Comparing the Psychometric Properties of the EQ-5D-3L and EQ-5D-5L Descriptive Systems and Utilities in Atopic Dermatitis

Overview

Journal Eur J Health Econ

Specialty Health Services

Date 2022 Apr 12

PMID 35412162

Authors

Kamilla Koszoru

Krisztina Hajdu

Valentin Brodszky

Alex Bato

L Hunor Gergely

Aniko Kovacs

Zsuzsanna Beretzky

Miklos Sardy

Andrea Szegedi

Fanni Rencz

Affiliations

Soon will be listed here.

Abstract

Background: Atopic dermatitis (AD) is a common chronic inflammatory skin disorder affecting up to 10% of adults. The EQ-5D is the most commonly used generic preference-accompanied measure to generate quality-adjusted life years (QALYs) for economic evaluations.

Objectives: We aimed to compare psychometric properties of the three-level and five-level EQ-5D (EQ-5D-3L and EQ-5D-5L) in adult patients with AD.

Methods: In a multicentre cross-sectional study, 218 AD patients with a broad range of severity completed the EQ-5D-3L, EQ-5D-5L, Dermatology Life Quality Index (DLQI) and Skindex-16. Disease severity outcomes included the Investigator Global Assessment, Eczema Area and Severity Index and the objective SCORing Atopic Dermatitis.

Results: A good agreement was established between the two EQ-5D versions with an intraclass correlation coefficient of 0.815 (95% CI 0.758-0.859, p < 0.001). Overall, 33 different health state profiles occurred in the EQ-5D-3L and 84 in the EQ-5D-5L. Compared to the EQ-5D-3L, ceiling effect was reduced for the mobility, self-care, usual activities and pain/discomfort dimensions by 4.6-11.5%. EQ-5D-5L showed higher average relative informativity (Shannon's evenness index: 0.64 vs. 0.59). EQ-5D-5L demonstrated better convergent validity with EQ VAS, DLQI and Skindex-16. The two measures were similar in distinguishing between groups of patients based on disease severity and skin-specific quality of life with a moderate or large effect size (η = 0.083-0.489).

Conclusion: Both instruments exhibited good psychometric properties in AD; however, the EQ-5D-5L was superior in terms of ceiling effects, informativity and convergent validity. We recommend the use of the EQ-5D-5L to measure health outcomes in clinical settings and for QALY calculations in AD.

Citing Articles

Comparison of health-related quality of life in atopic dermatitis, hidradenitis suppurativa, pemphigus and psoriasis.

Balazs P, Gaspar K, Gergely H, Hajdu K, Hollo P, Koszoru K Arch Dermatol Res. 2025; 317(1):291.

PMID: 39825944 PMC: 11742771. DOI: 10.1007/s00403-024-03786-4.

Disutility associated with social isolation and loneliness in Germany: results of a population survey using the EQ-5D-5L instrument.

Konig H, Hajek A Health Qual Life Outcomes. 2024; 22(1):110.

PMID: 39707414 PMC: 11662566. DOI: 10.1186/s12955-024-02329-9.

A Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index.

Vyas J, Johns J, Ali F, Ingram J, Salek S, Finlay A Acta Derm Venereol. 2024; 104:adv41120.

PMID: 39508500 PMC: 11559262. DOI: 10.2340/actadv.v104.41120.

The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality-of-life instruments: A systematic review.

Vyas J, Johns J, Abdelrazik Y, Ali F, Ingram J, Salek S J Eur Acad Dermatol Venereol. 2024; 39(3):631-679.

PMID: 39269008 PMC: 11851266. DOI: 10.1111/jdv.20321.

Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata.

Lloyd A, Aggio D, Dixon C, Law E, Price T Pharmacoecon Open. 2024; 8(5):715-725.

PMID: 38969921 PMC: 11362414. DOI: 10.1007/s41669-024-00504-8.

References

Poor A, Rencz F, Brodszky V, Gulacsi L, Beretzky Z, Hidvegi B . Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual Life Res. 2017; 26(12):3409-3419. DOI: 10.1007/s11136-017-1699-x. View

Chopra R, Vakharia P, Sacotte R, Patel N, Immaneni S, White T . Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017; 177(5):1316-1321. DOI: 10.1111/bjd.15641. View

Koo T, Li M . A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016; 15(2):155-63. PMC: 4913118. DOI: 10.1016/j.jcm.2016.02.012. View

Hanifin J, Thurston M, Omoto M, Cherill R, Tofte S, Graeber M . The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001; 10(1):11-8. DOI: 10.1034/j.1600-0625.2001.100102.x. View

Janssen M, Birnie E, Bonsel G . Evaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a US general population survey using Shannon's indices. Qual Life Res. 2007; 16(5):895-904. PMC: 1915610. DOI: 10.1007/s11136-006-9160-6. View

Yang Y, Brazier J, Longworth L . EQ-5D in skin conditions: an assessment of validity and responsiveness. Eur J Health Econ. 2014; 16(9):927-39. PMC: 4646948. DOI: 10.1007/s10198-014-0638-9. View

Rencz F, Brodszky V, Gulacsi L, Pentek M, Poor A, Hollo P . Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. J Eur Acad Dermatol Venereol. 2019; 33(7):e267-e269. DOI: 10.1111/jdv.15537. View

Birdi G, Cooke R, Knibb R . Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020; 59(4):e75-e91. DOI: 10.1111/ijd.14763. View

Bland J, Altman D . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476):307-10. View

10.

Geraerds A, Bonsel G, Janssen M, Finch A, Polinder S, Haagsma J . Methods Used to Identify, Test, and Assess Impact on Preferences of Bolt-Ons: A Systematic Review. Value Health. 2021; 24(6):901-916. DOI: 10.1016/j.jval.2020.12.011. View

11.

Rencz F, Poor A, Pentek M, Hollo P, Karpati S, Gulacsi L . A detailed analysis of 'not relevant' responses on the DLQI in psoriasis: potential biases in treatment decisions. J Eur Acad Dermatol Venereol. 2017; 32(5):783-790. DOI: 10.1111/jdv.14676. View

12.

Rencz F, Mitev A, Szabo A, Beretzky Z, Poor A, Hollo P . A Rasch model analysis of two interpretations of 'not relevant' responses on the Dermatology Life Quality Index (DLQI). Qual Life Res. 2021; 30(8):2375-2386. PMC: 8298357. DOI: 10.1007/s11136-021-02803-7. View

13.

Rencz F, Gulacsi L, Drummond M, Golicki D, Rupel V, Simon J . EQ-5D in Central and Eastern Europe: 2000-2015. Qual Life Res. 2016; 25(11):2693-2710. DOI: 10.1007/s11136-016-1375-6. View

14.

Yang Y, Rowen D, Brazier J, Tsuchiya A, Young T, Longworth L . An exploratory study to test the impact on three "bolt-on" items to the EQ-5D. Value Health. 2015; 18(1):52-60. PMC: 4309886. DOI: 10.1016/j.jval.2014.09.004. View

15.

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

16.

Vilsboll A, Kragh N, Hahn-Pedersen J, Jensen C . Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study. Qual Life Res. 2020; 29(9):2529-2539. PMC: 7434755. DOI: 10.1007/s11136-020-02499-1. View

17.

Calabrese L, Malvaso D, Chiricozzi A, Tambone S, DUrso D, Guerriero C . Baricitinib: therapeutic potential for moderate to severe atopic dermatitis. Expert Opin Investig Drugs. 2020; 29(10):1089-1098. DOI: 10.1080/13543784.2020.1800639. View

18.

Kuznik A, Bego-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham C . Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults. Dermatol Ther (Heidelb). 2017; 7(4):493-505. PMC: 5698200. DOI: 10.1007/s13555-017-0201-6. View

19.

Rehal B, Armstrong A, Armstrong A . Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One. 2011; 6(4):e17520. PMC: 3076368. DOI: 10.1371/journal.pone.0017520. View

20.

Rencz F, Brodszky V, Gulacsi L, Golicki D, Ruzsa G, Pickard A . Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Value Health. 2020; 23(9):1235-1245. DOI: 10.1016/j.jval.2020.03.019. View